CL2007001992A1 - Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege - Google Patents

Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege

Info

Publication number: CL2007001992A1
Authority: CL; Chile
Prior art keywords: compound; pyrimidilciclopentanos; neurodege; hyperproliferant; cardiovascular
Prior art date: 2006-07-06

Application number

CL200701992A

Other languages

English (en)

Inventor

Ian S Blake James F X Mitchell

Original Assignee

Array Biopharma Inc Genentech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-06

Filing date

2007-07-06

Publication date

2008-07-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007001992(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-07-06 Application filed by Array Biopharma Inc Genentech filed Critical Array Biopharma Inc Genentech

2008-07-18 Publication of CL2007001992A1 publication Critical patent/CL2007001992A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)

CL200701992A 2006-07-06 2007-07-06 Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege CL2007001992A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US81876206P	2006-07-06	2006-07-06

Publications (1)

Publication Number	Publication Date
CL2007001992A1 true CL2007001992A1 (es)	2008-07-18

Family

ID=38686844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200701992A CL2007001992A1 (es)	2006-07-06	2007-07-06	Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege

Country Status (31)

Country	Link
US (3)	US8003651B2 (es)
EP (1)	EP2049500B1 (es)
JP (3)	JP5268904B2 (es)
KR (2)	KR101527232B1 (es)
CN (2)	CN103288753A (es)
AR (1)	AR061844A1 (es)
AT (1)	ATE523499T1 (es)
AU (1)	AU2007269052B2 (es)
BR (1)	BRPI0713555A2 (es)
CA (1)	CA2656618C (es)
CL (1)	CL2007001992A1 (es)
CO (1)	CO6160229A2 (es)
CR (2)	CR10601A (es)
CY (1)	CY1112142T1 (es)
DK (1)	DK2049500T3 (es)
ES (1)	ES2372955T3 (es)
HR (1)	HRP20110882T1 (es)
IL (1)	IL196051A (es)
MA (1)	MA30952B1 (es)
MX (1)	MX2008016203A (es)
MY (1)	MY147628A (es)
NO (1)	NO20090580L (es)
NZ (1)	NZ573979A (es)
PL (1)	PL2049500T3 (es)
PT (1)	PT2049500E (es)
RS (1)	RS52210B (es)
RU (1)	RU2481336C2 (es)
SI (1)	SI2049500T1 (es)
TW (1)	TWI428335B (es)
UA (1)	UA99597C2 (es)
WO (1)	WO2008006032A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100047338A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
MX2008016203A (es)	2006-07-06	2009-01-27	Array Biopharma Inc	Ciclopenta [d] pirimidinas como inhibidores de la proteina cinasa akt.
JP5231411B2 (ja) *	2006-07-06	2013-07-10	アレイバイオファーマ、インコーポレイテッド	Ａｋｔプロテインキナーゼ阻害剤としてのジヒドロチエノピリミジン
DE602007011628D1 (de) *	2006-07-06	2011-02-10	Array Biopharma Inc	Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
UA95641C2 (xx) *	2006-07-06	2011-08-25	Эррей Биофарма Инк.	Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
AU2014201211B2 (en) *	2006-07-06	2016-04-14	Array Biopharma Inc.	Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en)	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR101624361B1 (ko)	2007-07-05	2016-05-25	어레이 바이오파마 인크.	Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en)	2007-07-05	2014-09-30	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CA2692502C (en) *	2007-07-05	2016-03-01	Array Biopharma Inc.	Pyrimidyl cyclopentanes as akt protein kinase inhibitors
CA2711614A1 (en)	2008-01-08	2009-07-16	Array Biopharma Inc.	Pyrrolopyridines as kinase inhibitors
CA2711782C (en)	2008-01-09	2017-01-03	Array Biopharma Inc.	5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
NZ586720A (en) *	2008-01-09	2012-11-30	Array Biopharma Inc	Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
EP2247578B1 (en) *	2008-01-09	2013-05-22	Array Biopharma, Inc.	Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
PE20091315A1 (es)	2008-01-09	2009-09-21	Array Biopharma Inc	Ciclopentanos de pirimidilo como inhibidores de la proteina cinasa akt
ES2392014T3 (es)	2008-01-09	2012-12-03	Array Biopharma, Inc.	Pirazolopiridinas como inhibidores de la cinasa
CA2761389A1 (en)	2009-02-05	2010-08-12	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US20100233733A1 (en) *	2009-02-10	2010-09-16	Nodality, Inc., A Delaware Corporation	Multiple mechanisms for modulation of the pi3 kinase pathway
CN103038643A (zh) *	2010-04-16	2013-04-10	基因泰克公司	作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a
MY179607A (en)	2011-04-01	2020-11-11	Genentech Inc	Combinations of akt inhibitor compounds and abiraterone, and methods of use
BR112013025397A2 (pt)	2011-04-01	2019-09-24	Deepak Sampath	combinação de um composto, composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, uso, kit, produto, método para tratamento de um distúrbio hiperproliferativo e método para tratamento de uma doença ou afecção modulada por quinase akt em um mamífero
PT2892900T (pt)	2012-09-10	2017-11-06	Principia Biopharma Inc	Compostos de pirazolopirimidina como inibidores de cinase
AU2014236135A1 (en)	2013-03-14	2015-09-10	Thomas Jefferson University	Androgen receptor down-regulating agents and uses thereof
WO2015013579A1 (en)	2013-07-26	2015-01-29	Update Pharma Inc.	Compositions to improve the therapeutic benefit of bisantrene
EP3033088A4 (en)	2013-08-12	2017-03-08	Tokai Pharmaceuticals, Inc.	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
MX385726B (es)	2013-11-15	2025-03-18	Hoffmann La Roche	Procesos para la preparación de compuestos de pirimidinilciclopentano.
PT3107544T (pt)	2014-02-21	2021-01-05	Principia Biopharma Inc	Sais e forma sólida de um inibidor de btk
CN106714811A (zh) *	2014-08-27	2017-05-24	佩普蒂梅德股份有限公司	抗肿瘤组合物和方法
CA2970723C (en)	2014-12-18	2023-09-05	Principia Biopharma Inc.	Treatment of pemphigus
EP3313839A1 (en)	2015-06-24	2018-05-02	Principia Biopharma Inc.	Tyrosine kinase inhibitors
WO2017156350A1 (en)	2016-03-09	2017-09-14	K-Gen, Inc.	Methods of cancer treatment
IL293621B2 (en)	2016-06-29	2023-09-01	Principia Biopharma Inc	Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
JP2019537585A (ja)	2016-10-28	2019-12-26	アイカーンスクールオブメディスンアットマウントシナイ	Ｅｚｈ２媒介性がんを治療するための組成物および方法
US11766455B2 (en)	2017-12-14	2023-09-26	Ezy Biotech Llc	Subject-specific tumor inhibiting cells and the use thereof
US12310967B2 (en)	2017-12-21	2025-05-27	Gliapharm Sa	Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US12274703B2 (en)	2017-12-21	2025-04-15	Gliapharm Sa	Compositions and methods of treatment for neurological disorders comprising a dementia
CN112154146A (zh) *	2018-03-06	2020-12-29	西奈山伊坎医学院	丝氨酸苏氨酸激酶(akt)降解/破坏化合物和使用方法
TWI830733B (zh) *	2018-05-11	2024-02-01	中國大陸商迪哲（江蘇）醫藥有限公司	環戊烷化合物
IT201800005561A1 (it) *	2018-05-21	2019-11-21		Metodo per la pulizia dei denti mediante una composizione in polvere a base di idrossiapatite.
AU2019288740A1 (en)	2018-06-21	2021-01-14	Icahn School Of Medicine At Mount Sinai	WD40 repeat domain protein 5 (WDR5) degradation / disruption compounds and methods of use
WO2020132378A2 (en)	2018-12-22	2020-06-25	Gliapharm Sa	Compositions and methods of treatment for neurological disorders comprising depression
JP7617005B2 (ja)	2019-01-29	2025-01-17	南京正大天晴制薬有限公司	Ａｋｔ阻害剤
CA3137916A1 (en)	2019-05-06	2020-11-12	Ichan School Of Medicine At Mount Sinai	Heterobifunctional compounds as degraders of hpk1
CA3154257A1 (en)	2019-10-14	2021-04-22	Principia Biopharma Inc.	Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
JP7769388B2 (ja)	2019-12-12	2025-11-13	ティンセラピューティクス，インコーポレイテッド	聴覚損失の予防及び治療のための組成物及び方法
AU2021209884A1 (en)	2020-01-22	2022-09-15	Principia Biopharma Inc.	Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021228223A1 (zh) *	2020-05-15	2021-11-18	南京正大天晴制药有限公司	氘代akt激酶抑制剂
US12103924B2 (en)	2020-06-01	2024-10-01	Icahn School Of Medicine At Mount Sinai	Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CA3186568A1 (en)	2020-07-22	2022-01-27	Changyou MA	Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof
CA3186565A1 (en) *	2020-07-22	2022-01-27	Lei Miao	Unit dosage composition of akt inhibitor
CN117677614A (zh) *	2021-12-17	2024-03-08	中国医药研究开发中心有限公司	具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3885035A (en)	1972-04-05	1975-05-20	Sandoz Ag	Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US3956495A (en)	1973-10-30	1976-05-11	Eli Lilly And Company	2,4-Diaminoquinazolines as antithrombotic agents
US3966936A (en)	1974-02-21	1976-06-29	Pfizer Inc.	Piperazino quinazoline bronchodilators
US4060615A (en)	1976-02-18	1977-11-29	Mead Johnson & Company	2-Piperazinyl-6,7-dimethoxyquinazolines
US4051412A (en) *	1976-09-02	1977-09-27	General Electric Company	Discharge lamp operating circuit
JPS562968A (en)	1979-06-21	1981-01-13	Mitsubishi Yuka Yakuhin Kk	Novel pyrimidine derivative
JPS6270A (ja)	1985-03-07	1987-01-06	Sankyo Co Ltd	シクロペンタ〔ｄ〕ピリミジン誘導体
DE3752141T2 (de)	1986-02-24	1998-03-26	Mitsui Petrochemical Ind	Mittel zur behandlung von neuropathie
US4871739A (en)	1987-01-21	1989-10-03	Merck & Co., Inc.	Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents
US4889856A (en)	1987-08-31	1989-12-26	Merck & Co., Inc.	7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as β-blockers
US4994464A (en)	1987-08-31	1991-02-19	Merck & Co., Inc.	Piperazinylpyrimidines as β-adrenergic receptor blockers
MX19185A (es)	1989-01-20	1993-12-01	Pfizer	Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
JP2932693B2 (ja)	1992-10-05	1999-08-09	宇部興産株式会社	ピリミジン化合物
WO1995003286A1 (en)	1993-07-23	1995-02-02	The Green Cross Corporation	Triazole derivative and pharmaceutical use thereof
GB9416189D0 (en)	1994-08-10	1994-09-28	Merck Sharp & Dohme	Therapeutic agents
ES2201112T3 (es)	1994-08-13	2004-03-16	Yuhan Corporation	Nuevos derivados de pirimidina y procedimientos para su preparacion.
US5525625A (en)	1995-01-24	1996-06-11	Warner-Lambert Company	2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US7125880B1 (en)	1995-06-06	2006-10-24	Pfizer Inc.	Corticotropin releasing factor antagonists
ZA979961B (en)	1996-11-15	1999-05-05	Lilly Co Eli	5-HT1F agonists
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6310060B1 (en)	1998-06-24	2001-10-30	Warner-Lambert Company	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
EP0993437B1 (en)	1997-07-01	2006-11-08	Warner-Lambert Company Llc	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
US6506798B1 (en)	1997-07-01	2003-01-14	Warner-Lambert Company	4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
HUP0003731A3 (en)	1997-07-01	2002-11-28	Warner Lambert Co	4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US6821963B2 (en)	1997-07-01	2004-11-23	Warner-Lambert Company	4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
ATE496035T1 (de)	1998-03-31	2011-02-15	Kyowa Hakko Kirin Co Ltd	Stickstoffenthaltende heterocyclische verbindungen
DE19853278A1 (de)	1998-11-19	2000-05-25	Aventis Pharma Gmbh	Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CA2358438A1 (en)	1999-01-07	2000-07-13	David Thomas Dudley	Antiviral method using mek inhibitors
WO2000040235A2 (en)	1999-01-07	2000-07-13	Warner-Lambert Company	Treatment of asthma with mek inhibitors
AU2201500A (en)	1999-01-13	2000-08-01	Warner-Lambert Company	Benzenesulfonamide derivatives and their use as mek inhibitors
DE69926800T2 (de)	1999-01-13	2006-05-18	Warner-Lambert Company Llc	Benzoheterozyklen und ihre verwendung als mek inhibitoren
US6455582B1 (en)	1999-01-13	2002-09-24	Warner-Lambert Company	Sulohydroxamic acids and sulohyroxamates and their use as MEK inhibitors
BR9916896A (pt)	1999-01-13	2001-11-20	Warner Lambert Co	Diaril aminas substituìdas com 1-heterociclo
AU2483400A (en)	1999-01-13	2000-08-01	Warner-Lambert Company	4'heteroaryl diarylamines
CA2348236A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
GB9910577D0 (en)	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds
EP1202732A2 (en)	1999-07-16	2002-05-08	Warner-Lambert Company Llc	Method for treating chronic pain using mek inhibitors
WO2001005390A2 (en)	1999-07-16	2001-01-25	Warner-Lambert Company	Method for treating chronic pain using mek inhibitors
EP1202724B1 (en)	1999-07-16	2003-10-01	Warner-Lambert Company	Method for treating chronic pain using mek inhibitors
IL147619A0 (en)	1999-07-16	2002-08-14	Warner Lambert Co	Method for treating chronic pain using mek inhibitors
GB0003636D0 (en) *	2000-02-16	2000-04-05	Smithkline Beecham Plc	Novel compounds
BR0109188A (pt)	2000-03-15	2003-03-18	Warner Lambert Co	Diarilaminas 5-amida substituìdas como inibidores de mex
DZ3401A1 (fr)	2000-07-19	2002-01-24	Warner Lambert Co	Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
EA200300187A1 (ru)	2000-08-25	2003-08-28	УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си	Способ получения n-арилантраниловых кислот и их производных
EP1317450B1 (en)	2000-09-15	2006-11-22	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7067532B2 (en)	2000-11-02	2006-06-27	Astrazeneca	Substituted quinolines as antitumor agents
WO2002083139A1 (en)	2001-04-10	2002-10-24	Merck & Co., Inc.	Inhibitors of akt activity
JP2004528349A (ja)	2001-04-30	2004-09-16	グラクソ　グループ　リミテッド	副腎皮質刺激ホルモン放出因子（ｃｒｆ）のアンタゴニストとしての縮合ピリミジン類
RU2003134646A (ru) *	2001-04-30	2005-04-20	Глэксо Груп Лимитед (GB)	Конденсированные пиримидины в качестве антагонистов кортикотропинвысокобождающего фактора (crf)
AU2002336462A1 (en)	2001-09-06	2003-03-24	Millennium Pharmaceuticals, Inc.	Piperazine and homopiperazine compounds
AU2002357043B2 (en)	2001-12-06	2008-04-24	Merck Sharp & Dohme Corp.	Mitotic kinesin inhibitors
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
US6924290B2 (en)	2002-01-23	2005-08-02	Bayer Pharmaceuticals Corporation	Rho-kinase inhibitors
TW200306819A (en)	2002-01-25	2003-12-01	Vertex Pharma	Indazole compounds useful as protein kinase inhibitors
KR20040098013A (ko)	2002-03-13	2004-11-18	어레이 바이오파마 인크.	Ｍｅｋ 억제제로서의 ｎ3 알킬화된 벤즈이미다졸 유도체
US7235537B2 (en)	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
PA8569301A1 (es)	2002-03-13	2004-10-08	Array Biopharma Inc	"derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimidazole derivatives as mek inhibitors"
EP1494676B1 (en)	2002-04-08	2013-05-08	Merck Sharp & Dohme Corp.	Fused quinoxaline derivatives as inhibitors of akt activity
EP1496896A4 (en)	2002-04-08	2007-10-31	Merck & Co Inc	AKT INHIBITORS EFFECT
EP1496906A4 (en)	2002-04-08	2006-05-03	Merck & Co Inc	HEMMER OF ACT ACTIVITY
US20050182256A1 (en)	2002-04-08	2005-08-18	Duggan Mark E.	Inhibitors of akt activity
CA2484968A1 (en)	2002-05-10	2003-11-20	Neurocrine Biosciences, Inc.	Substituted piperazine as melanocortin receptors ligands
US20040102360A1 (en)	2002-10-30	2004-05-27	Barnett Stanley F.	Combination therapy
WO2004041162A2 (en)	2002-10-30	2004-05-21	Merck & Co., Inc.	Inhibitors of akt activity
EA200500721A1 (ru)	2002-11-28	2005-12-29	Шеринг Акциенгезельшафт	Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
GB0308208D0 (en)	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
US7638530B2 (en)	2003-04-24	2009-12-29	Merck & Co., Inc.	Inhibitors of Akt activity
US6994380B2 (en) *	2003-06-02	2006-02-07	Cooke Jr Charles M	High pressure quick connect coupling and seal
WO2004111014A1 (en)	2003-06-06	2004-12-23	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
KR20060118398A (ko)	2003-08-05	2006-11-23	버텍스 파마슈티칼스 인코포레이티드	전압 개폐 이온 채널 억제제로서의 축합 피라미딘 화합물
EP1656354B1 (en)	2003-08-12	2007-09-26	F.Hoffmann-La Roche Ag	Tetrahydroquinazoline derivatives as cfr antagonists
CA2538026A1 (en)	2003-09-09	2005-03-24	Ono Pharmaceutical Co., Ltd.	Crf antagonists and heterobicyclic compounds
WO2005039564A1 (en)	2003-10-02	2005-05-06	Vertex Pharmaceuticals Incorporated	Phthalimide compounds useful as protein kinase inhibitors
US20050130954A1 (en)	2003-11-21	2005-06-16	Mitchell Ian S.	AKT protein kinase inhibitors
EP1750727A2 (en)	2004-04-23	2007-02-14	Exelixis, Inc.	Kinase modulators and methods of use
WO2006000589A1 (en)	2004-06-28	2006-01-05	Altana Pharma Ag	4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
US20060025074A1 (en)	2004-07-30	2006-02-02	Chih-Ming Liang	Bluetooth-based headset
TWM266655U (en)	2004-09-23	2005-06-01	Blueexpert Technology Corp	Bluetooth earphone device capable of wirelessly receiving and transmitting stereo sound signal and digital information signal
TW200621257A (en)	2004-10-20	2006-07-01	Astellas Pharma Inc	Pyrimidine derivative fused with nonaromatic ring
UY29177A1 (es)	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
US7994172B2 (en)	2004-12-28	2011-08-09	Exelixis, Inc.	[1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
JP2008531542A (ja)	2005-02-24	2008-08-14	ファイザー・プロダクツ・インク	抗癌剤として有用な二環式複素芳香族誘導体
ZA200710379B (en)	2005-05-20	2009-05-27	Vertex Pharma	Pyrrolopyridines useful as inhibitors of protein kinase
UY29610A1 (es)	2005-06-21	2007-01-31	Cancer Rec Tech Ltd	Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
CA2625109A1 (en)	2005-10-13	2007-04-19	Glaxo Group Limited	Pyrrolopyrimidine derivatives as syk inhibitors
PE20071164A1 (es)	2005-12-28	2008-01-11	Takeda Pharmaceutical	Compuestos heterociclico fusionado como antagonista del receptor mineralocorticoide
US20090124610A1 (en)	2006-04-25	2009-05-14	Gordon Saxty	Pharmaceutical compounds
KR20090024834A (ko)	2006-07-05	2009-03-09	인터뮨, 인크.	Ｃ형 간염 바이러스 복제의 신규 억제제
KR101398264B1 (ko)	2006-07-06	2014-05-26	글락소 그룹 리미티드	Ｐ２ｘ７수용체 길항제로서의 치환된 ｎ페닐메틸５옥소프롤린２아미드 및 그의 사용 방법
UA95641C2 (xx)	2006-07-06	2011-08-25	Эррей Биофарма Инк.	Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
GB0613518D0 (en)	2006-07-06	2006-08-16	Phytopharm Plc	Chemical compounds
MX2008016203A (es)	2006-07-06	2009-01-27	Array Biopharma Inc	Ciclopenta [d] pirimidinas como inhibidores de la proteina cinasa akt.
TW200808325A (en)	2006-07-06	2008-02-16	Astrazeneca Ab	Novel compounds
US7910747B2 (en)	2006-07-06	2011-03-22	Bristol-Myers Squibb Company	Phosphonate and phosphinate pyrazolylamide glucokinase activators
WO2008012635A2 (en)	2006-07-26	2008-01-31	Pfizer Products Inc.	Amine derivatives useful as anticancer agents

2007
- 2007-07-05 MX MX2008016203A patent/MX2008016203A/es active IP Right Grant
- 2007-07-05 KR KR1020097002436A patent/KR101527232B1/ko not_active Expired - Fee Related
- 2007-07-05 JP JP2009518634A patent/JP5268904B2/ja not_active Expired - Fee Related
- 2007-07-05 PL PL07799329T patent/PL2049500T3/pl unknown
- 2007-07-05 EP EP07799329A patent/EP2049500B1/en active Active
- 2007-07-05 WO PCT/US2007/072876 patent/WO2008006032A1/en not_active Ceased
- 2007-07-05 PT PT07799329T patent/PT2049500E/pt unknown
- 2007-07-05 SI SI200730779T patent/SI2049500T1/sl unknown
- 2007-07-05 DK DK07799329.3T patent/DK2049500T3/da active
- 2007-07-05 KR KR1020157007785A patent/KR20150041164A/ko not_active Withdrawn
- 2007-07-05 CA CA2656618A patent/CA2656618C/en not_active Expired - Fee Related
- 2007-07-05 US US11/773,946 patent/US8003651B2/en not_active Expired - Fee Related
- 2007-07-05 HR HR20110882T patent/HRP20110882T1/hr unknown
- 2007-07-05 ES ES07799329T patent/ES2372955T3/es active Active
- 2007-07-05 RU RU2009103899/04A patent/RU2481336C2/ru not_active IP Right Cessation
- 2007-07-05 NZ NZ573979A patent/NZ573979A/en not_active IP Right Cessation
- 2007-07-05 RS RS20110519A patent/RS52210B/sr unknown
- 2007-07-05 UA UAA200900828A patent/UA99597C2/ru unknown
- 2007-07-05 CN CN2013101365018A patent/CN103288753A/zh active Pending
- 2007-07-05 CN CN2007800330546A patent/CN101631778B/zh not_active Expired - Fee Related
- 2007-07-05 AT AT07799329T patent/ATE523499T1/de active
- 2007-07-05 MY MYPI20090025A patent/MY147628A/en unknown
- 2007-07-05 AU AU2007269052A patent/AU2007269052B2/en not_active Expired - Fee Related
- 2007-07-05 BR BRPI0713555-6A patent/BRPI0713555A2/pt not_active Application Discontinuation
- 2007-07-06 AR ARP070103035A patent/AR061844A1/es unknown
- 2007-07-06 CL CL200701992A patent/CL2007001992A1/es unknown
- 2007-07-06 TW TW096124776A patent/TWI428335B/zh not_active IP Right Cessation
2008
- 2008-12-18 IL IL196051A patent/IL196051A/en not_active IP Right Cessation
2009
- 2009-02-03 MA MA31611A patent/MA30952B1/fr unknown
- 2009-02-04 CO CO09010511A patent/CO6160229A2/es unknown
- 2009-02-05 CR CR10601A patent/CR10601A/es unknown
- 2009-02-05 NO NO20090580A patent/NO20090580L/no not_active Application Discontinuation
2011
- 2011-06-14 US US13/160,351 patent/US8846681B2/en not_active Expired - Fee Related
- 2011-12-05 CY CY20111101202T patent/CY1112142T1/el unknown
2013
- 2013-05-07 JP JP2013097595A patent/JP5586735B2/ja not_active Expired - Fee Related
- 2013-06-05 JP JP2013118690A patent/JP2013231040A/ja not_active Withdrawn
2014
- 2014-05-09 CR CR20140215A patent/CR20140215A/es unknown
- 2014-08-11 US US14/456,670 patent/US20140349996A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20140349996A1 (en)	2014-11-27
PL2049500T3 (pl)	2012-02-29
ATE523499T1 (de)	2011-09-15
MA30952B1 (fr)	2009-12-01
HK1126758A1 (en)	2009-09-11
US8003651B2 (en)	2011-08-23
UA99597C2 (ru)	2012-09-10
US8846681B2 (en)	2014-09-30
CA2656618A1 (en)	2008-01-10
CA2656618C (en)	2014-08-26
RS52210B (sr)	2012-10-31
PT2049500E (pt)	2011-12-23
BRPI0713555A2 (pt)	2012-03-20
SI2049500T1 (sl)	2012-01-31
CR10601A (es)	2009-02-20
ES2372955T3 (es)	2012-01-30
CN103288753A (zh)	2013-09-11
NO20090580L (no)	2009-04-06
JP2013209381A (ja)	2013-10-10
TW200817372A (en)	2008-04-16
NZ573979A (en)	2012-02-24
EP2049500A1 (en)	2009-04-22
AU2007269052B2 (en)	2014-10-23
KR101527232B1 (ko)	2015-06-09
RU2009103899A (ru)	2010-08-20
JP5268904B2 (ja)	2013-08-21
CR20140215A (es)	2014-07-11
HRP20110882T1 (hr)	2012-01-31
CN101631778B (zh)	2013-05-08
AU2007269052A1 (en)	2008-01-10
KR20090029287A (ko)	2009-03-20
KR20150041164A (ko)	2015-04-15
CN101631778A (zh)	2010-01-20
CY1112142T1 (el)	2015-11-04
JP2013231040A (ja)	2013-11-14
US20080058327A1 (en)	2008-03-06
RU2481336C2 (ru)	2013-05-10
AR061844A1 (es)	2008-09-24
EP2049500B1 (en)	2011-09-07
CO6160229A2 (es)	2010-05-20
IL196051A0 (en)	2009-09-01
IL196051A (en)	2012-10-31
TWI428335B (zh)	2014-03-01
MX2008016203A (es)	2009-01-27
DK2049500T3 (da)	2011-12-12
US20110245230A1 (en)	2011-10-06
JP2009542721A (ja)	2009-12-03
WO2008006032A1 (en)	2008-01-10
MY147628A (en)	2012-12-31
JP5586735B2 (ja)	2014-09-10

Publication	Publication Date	Title
CL2007001992A1 (es)	2008-07-18	Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
CL2007001993A1 (es)	2008-06-20	Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
CL2007002916A1 (es)	2008-04-18	Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
CL2007002866A1 (es)	2008-07-04	Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
CL2007002018A1 (es)	2008-05-09	Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2007003299A1 (es)	2008-08-22	Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2007002967A1 (es)	2008-04-18	Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
CL2007002641A1 (es)	2008-06-20	Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
BRPI0806531A2 (pt)	2014-04-22	Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CL2007003033A1 (es)	2008-05-16	Compuestos derivados de benzoilamino heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la diabetes tipo ii.
CL2008001273A1 (es)	2008-09-22	Compuestos derivados de heterociclos, inhibidores de proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la inflamacion, enfermedad cardiovascular, asma
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007003686A1 (es)	2008-06-27	Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
CL2007002207A1 (es)	2008-02-01	Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2007000806A1 (es)	2008-05-30	Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007003614A1 (es)	2008-06-20	Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis
CL2008001076A1 (es)	2008-10-24	Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
BRPI0922233A2 (pt)	2018-05-29	compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
CL2007001630A1 (es)	2008-02-08	Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
CL2007003540A1 (es)	2008-06-13	Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2007003672A1 (es)	2008-07-25	Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.